What is ModeX Therapeutics?
Founded in 2019, ModeX Therapeutics is a North American-based biotechnology firm specializing in the creation of modular platforms designed to integrate multiple biologics into singular therapeutic molecules. The company's innovative approach targets complex diseases, with a primary focus on immuno-oncology and infectious diseases. Through its robust research and development services, ModeX Therapeutics aims to revolutionize drug development by combining diverse biological components into unified treatments, operating within the business services sector with a strong emphasis on scientific research and therapeutic innovation.
How much funding has ModeX Therapeutics raised?
ModeX Therapeutics has raised a total of $35M across 1 funding round:
Other Financing Round
$35M
Other Financing Round (2024): $35M with participation from Biomedical Advanced Research and Development Authority (BARDA
Key Investors in ModeX Therapeutics
Biomedical Advanced Research and Development Authority (BARDA
BARDA is a key U.S. government entity focused on enhancing national health security by supporting the development of medical countermeasures. They partner with innovators to advance promising technologies from research to regulatory approval, particularly for chemical, biological, radiological, and nuclear threats, as well as vaccines and therapeutics.
What's next for ModeX Therapeutics?
The recent major strategic investment signifies a critical juncture for ModeX Therapeutics, likely enabling the company to scale its operations, advance its pipeline of modular biologic therapies, and potentially expand its research and development capabilities. This capital infusion is expected to fuel further innovation in tackling complex diseases, reinforcing its position in the competitive biotechnology landscape and paving the way for future clinical advancements and market introductions.
See full ModeX Therapeutics company page
